Kin Therapeutics is focused on finding a therapy for you and your family.

Kin Therapeutics is focused on developing treatments for rare genetic disease of the extracellular matrix. Our focus on Ehlers Danlos, Marfan, and Osteogenesis Imperfecta  help us build a deep scientific and clinical understanding of these connective tissue diseases. Our approach is very personalized. We work directly with individuals impacted by these diseases.  Kin Therapeutics forms partnerships with families to advance feasible gene or cell therapies designed specifically for the mutation afflicting the patient. Our company symbol and inspiration is the tree of life and knowledge. Families are connected through genetics and shared experiences. The founder has vascular Ehlers Danlos and knows first hand the challenges that come with the disease. Kin Therapeutics wants to help other families find cures to the rare connective tissue diseases that impact them.
Ehlers Danlos, Marfan Syndrome and Osteogenesis Imperfecta are three of the most common heritable connective tissue diseases. The incidence of these orphan diseases ranges from 1 in 5,000 for Marfan Syndrome to 1 in 100,000 live births for vEDS. Therapies developed for orphan diseases recieve market protections and other benefits. Current treatments for these diseases include highly invasive, risky and expensive surgery. Prevention and mitigation of surgical intervention would be a welcome alternative. Abnormalities in collagen and other extracellular matrix components are common in cardiovascular, pulmonary, dermatalogic and orthopedic diseases. We will leverage our knowledge to find treatements for more common fibrotic diseases.